Artificial Intelligence

Abeona Therapeutics' new treatment center for ZEVASKYN marks a strategic leap in gene therapy access, but what does it mean for patients and the market?

Ghost Robotics' new arm gives its Vision 60 the power to act. This leap from seeing to doing has huge implications for industries from defense to healthcare.

Impressive drill results from Lapon Canyon are turning heads, but the discovery of monzonite-hosted gold suggests a much larger story is unfolding.

With a new $6.5M investment, Double is tackling the accounting talent crisis with AI that empowers professionals, not replaces them. Here's why.

As esports races toward a $7.5B market, specialized hardware is king. Inside ZOWIE's strategy to win the high-stakes game of competitive tech.

A once-failed class of weight-loss drugs is back with a new design. Corbus Pharma's early data suggests it may have solved the safety puzzle.

Brii Biosciences partners with OpenBench, using an AI platform where they only pay for results. Is this the future of de-risking pharmaceutical R&D?

After a decade of failed trials, a new drug shows promise in treating resistant lung cancer by reawakening the immune system and halting its spread.

A breakthrough genetic therapy for ALS offers hope, but a split verdict from Canadian health agencies reveals the tough calculus of innovation versus cost.

Beyond its first-ever dividend, Covalon's true story is one of clinical innovation driving record sales, navigating market shifts, and funding global growth.

Promising interim data for a Parkinson's vaccine sends AC Immune's stock soaring, signaling a potential paradigm shift from symptom management to disease modification.

With AI-guided drills and a new discovery, Nevada King aims to transform its Atlanta mine into a major US gold asset. Will the market take notice?

Bristol Myers Squibb's Opdivo gets FDA priority review, backed by landmark data suggesting it could unseat a key competitor as the new gold standard.

Rezolute's stock plummets after its lead drug fails a key trial, raising questions about its future and highlighting the brutal realities of biotech.

Dreame's 2025 holiday sale isn't just about vacuums; it's a strategic play to conquer the UK market with premium tech at aggressive prices.

With a new board chair and a clear shareholder mandate, Edgewater Wireless is shifting from R&D to monetizing its game-changing Spectrum Slicing tech.

As AI-driven fakes flood the world, a new asset class is born: authenticity. Discover how GME and Reality Defender are monetizing trust for government.

With its pivotal trial fully enrolled, IDEAYA Biosciences is on track for a 2026 FDA filing for a new treatment in a rare, deadly eye cancer.

Fidelity and TIAA still lead, but strategic AI investments are fueling a surge from mid-tier players, redefining the competitive retirement landscape.

A single crypto campaign generates $53.5B in futures volume. We dissect MEXC's strategy and what it reveals about the exchange wars and token adoption.